Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Emory University | OTHER |
Not provided
Not provided
Not provided
This is a proof of concept safety study of an artificial intelligence based closed loop glucose control system designed for use in the intensive care unit setting.
The type 2 diabetic subjects in this study will have their glucose controlled to a range of 100-140 mg/dL by a novel artificial intelligence based closed loop glucose control system for a period of 24 hours. The subjects will consume three standardized meals during the 24 hour study period.
Tight glucose control in the intensive care unit (ICU) setting is difficult to achieve. The investigators hypothesize that a closed loop glucose control system based on artificial intelligence (AI) will improve upon the glucose control currently achieved by the current open loop manual methods, and that this improved glucose control may improve the outcomes of critically ill patients, including those with COVID-19.
This Earl Feasibility Study will test the ability of a prototype artificial intelligence based closed loop glucose control system named FUSION, to provide safe and effective glucose control in subjects with type 2 diabetes in a clinical research center (CRC) setting. Subjects with type 2 diabetes have been chosen as they are insulin resistant, which makes their insulin resistance profile similar to that of ICU patients. As this is the first in human study of a new medical device, the controlled environment of the CRC is preferable to the less controlled environment of an ICU setting.
The prototype FUSION system to be used in this study will consist to two Dexcom G6 continuous glucose monitors (CGM), the AI-based glucose control software run on an all-in-one medical computer, and two syringe pumps. The prototype system is housed on a medical cart. Based on the average glucose value of the two Dexcom G6 CGM's, and the rules of the FUSION systems AI-based glucose control software, the FUSION system will make rate adjustments every 5-10 minutes to the intravenous infusion rates of short acting insulin (NovoLog) and dextrose (D10NS) under its control, in an attempt to keep the subjects glucose in the range of 100-140 mg/dL. The FUSION system only requires entry of the subjects study identification number and weight in kilograms to initiate the system.
For safety reasons, the subjects will have their blood glucose independently measured every 10-60 minutes on a YSI 2900 glucose analyzer and the point of care Nova StatStrip system, throughout the 24 hour study period.
The study has halting criteria to avoid recurrent instances of severe hypoglycemia (< 54 mg/dL).
The average of the two CGM's, that is used by the FUSION system for glucose control, will be used for statistical analysis. In addition, both the average glucose value used by the FUSION system and each individual CGM system will be compared to the YSI glucose analyzer for correlation between systems using the Surveillance Error grid.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| FUSION closed loop glucose control system | Experimental | All subjects will be treated with the FUSION closed loop glucose control system for up to 24 hours |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| FUSION closed loop glucose control system | Device | The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session. |
| Measure | Description | Time Frame |
|---|---|---|
| Percent of All Glucose Values Within Glucose Range < 70 mg/dL | Calculated by dividing the number of glucose values < 70 mg/dl by the total number of all glucose values and then multiplying times 100 | From beginning of use of the FUSION system to end of use of the FUSION system, which will be a period of time of up to 24 hours |
| Percent of All Glucose Values Within Glucose Range 70-180 mg/dL | Calculated by dividing the number of glucose values in the 70-180 mg/dl range by the total number of all glucose values and then multiplying times 100 | From beginning of use of the FUSION system to end of use of the FUSION system, which will be a period of time of up to 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Percent of All Glucose Values Within Glucose Range < 54 mg/dL | Calculated by dividing the number of glucose values < 54 mg/dl by the total number of all glucose values and then multiplying times 100 | From beginning of use of the FUSION system to end of use of the FUSION system, which will be a period of time of up to 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Average Glucose Value | Calculate the average glucose value by adding up all glucose values and then dividing by the total number of glucose values that were added up | From beginning of use of the FUSION system to end of use of the FUSION system, which will be a period of time of up to 24 hours |
Inclusion Criteria:
Are 18-70 years of age, inclusive.
Can understand and sign an informed consent, communicate with the investigator, and understand and comply with the protocol requirements.
Have had a diagnosis of type 2 diabetes for a period of at least 3 months.
Use insulin injections at home for glucose control.
Have a hemoglobin A1c (HbA1c) in the range of 7.0 - 10.0%.
Have a hemoglobin in the normal range for sex:
Have adequate venous access sites in upper extremities.
Body weight between 40 - 150 kg.
Exclusion Criteria:
Have participated in an interventional medical, surgical, or pharmaceutical study within 30 days of screening.
Have a known hypersensitivity to any of the components of study treatment.
Have skin disease/injury at Dexcom G6 CGM insertion site(s) that would prevent insertion of the CGM.
Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be noncompliant.
Have a medical condition that in the opinion of the investigator could affect study participation and/or personal well-being.
Have a clinically significant history or presence of any of the following conditions:
For female subjects of potential childbearing age (age 18 to 55) they will be excluded if:
Have a positive COVID-19 test within 14 days of visit 3.
Have any COVID-19 related symptoms in the 14-day period prior to visit 3.
Have a known unprotected COVID-19 exposure in the 14-day period prior to visit 3.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Leon DeJournett, MD | Ideal Medical Technologies | Study Director |
| Francisco Pasquel, MD | Emory University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Emory University | Atlanta | Georgia | 30322 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27301982 | Background | DeJournett L, DeJournett J. In Silico Testing of an Artificial-Intelligence-Based Artificial Pancreas Designed for Use in the Intensive Care Unit Setting. J Diabetes Sci Technol. 2016 Nov 1;10(6):1360-1371. doi: 10.1177/1932296816653967. Print 2016 Nov. | |
| 28637358 | Background | DeJournett J, DeJournett L. Comparative Simulation Study of Glucose Control Methods Designed for Use in the Intensive Care Unit Setting via a Novel Controller Scoring Metric. J Diabetes Sci Technol. 2017 Nov;11(6):1207-1217. doi: 10.1177/1932296817711297. Epub 2017 Jun 22. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
3 subjects signed consents to be screened for eligibility.
Subjects recruited from the adult diabetes clinics of Emory Healthcare
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | FUSION Closed Loop Glucose Control System | All subjects will be treated with the FUSION closed loop glucose control system for up to 24 hours FUSION closed loop glucose control system: The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | FUSION Closed Loop Glucose Control System | All subjects will be treated with the FUSION closed loop glucose control system for up to 24 hours FUSION closed loop glucose control system: The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percent of All Glucose Values Within Glucose Range < 70 mg/dL | Calculated by dividing the number of glucose values < 70 mg/dl by the total number of all glucose values and then multiplying times 100 | Posted | Mean | Standard Deviation | Percentage of all glucose values | From beginning of use of the FUSION system to end of use of the FUSION system, which will be a period of time of up to 24 hours |
|
From beginning of use of the FUSION system until end of use of the FUSION system, up to 24 hours
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | FUSION Closed Loop Glucose Control System | All subjects will be treated with the FUSION closed loop glucose control system for up to 24 hours FUSION closed loop glucose control system: The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session. |
Not provided
Not provided
This was a small non-randomized safety study of a novel medical device. A formal statistical analysis plan was not used due to the limited number of participants
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Leon DeJournett/Chief Medical Officer | Ideal Medical Technologies | 8283379960 | leondej@idealmedtech.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Apr 12, 2022 | May 15, 2025 | Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Apr 20, 2022 | Jul 30, 2022 | ICF_001.pdf |
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Early Feasibility Safety Study
Not provided
Not provided
Not provided
Not provided
| Percent of All Glucose Values Within Glucose Range > 180 mg/dL |
Calculated by dividing the number of glucose values > 180 mg/dl by the total number of all glucose values and then multiplying times 100 |
| From beginning of use of the FUSION system to end of use of the FUSION system, which will be a period of time of up to 24 hours |
| Percentage of Coefficient of Variation | The glucose percentage of coefficient of variation is calculated by dividing the average glucose values standard deviation in mg/dL by the average glucose value in mg/dL, then multiplying times 100 to achieve a unitless percent value | From beginning of use of the FUSION system to end of use of the FUSION system, which will be a period of time of up to 24 hours |
| Percent of All Glucose Values Within Glucose Range > 250 mg/dL | Calculated by dividing the number of glucose values > 250 mg/dl by the total number of all glucose values and then multiplying times 100 | From beginning of use of the FUSION system to end of use of the FUSION system, which will be a period of time of up to 24 hours |
| 32006145 | Background | DeJournett J, Nekludov M, DeJournett L, Wallin M. Performance of a closed-loop glucose control system, comprising a continuous glucose monitoring system and an AI-based controller in swine during severe hypo- and hyperglycemic provocations. J Clin Monit Comput. 2021 Apr;35(2):317-325. doi: 10.1007/s10877-020-00474-2. Epub 2020 Jan 31. |
| 20167184 | Background | DeJournett L. Essential elements of the native glucoregulatory system, which, if appreciated, may help improve the function of glucose controllers in the intensive care unit setting. J Diabetes Sci Technol. 2010 Jan 1;4(1):190-8. doi: 10.1177/193229681000400124. |
| 32430456 | Background | Sardu C, D'Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, Maggi P, Coppola N, Paolisso G, Marfella R. Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? Diabetes Care. 2020 Jul;43(7):1408-1415. doi: 10.2337/dc20-0723. Epub 2020 May 19. |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Primary | Percent of All Glucose Values Within Glucose Range 70-180 mg/dL | Calculated by dividing the number of glucose values in the 70-180 mg/dl range by the total number of all glucose values and then multiplying times 100 | Posted | Mean | Standard Deviation | Percentage of all glucose values | From beginning of use of the FUSION system to end of use of the FUSION system, which will be a period of time of up to 24 hours |
|
|
|
| Secondary | Percent of All Glucose Values Within Glucose Range < 54 mg/dL | Calculated by dividing the number of glucose values < 54 mg/dl by the total number of all glucose values and then multiplying times 100 | Posted | Mean | Standard Deviation | Percentage of all glucose values | From beginning of use of the FUSION system to end of use of the FUSION system, which will be a period of time of up to 24 hours |
|
|
|
| Secondary | Percent of All Glucose Values Within Glucose Range > 180 mg/dL | Calculated by dividing the number of glucose values > 180 mg/dl by the total number of all glucose values and then multiplying times 100 | Posted | Mean | Standard Deviation | Percentage of all glucose values | From beginning of use of the FUSION system to end of use of the FUSION system, which will be a period of time of up to 24 hours |
|
|
|
| Secondary | Percentage of Coefficient of Variation | The glucose percentage of coefficient of variation is calculated by dividing the average glucose values standard deviation in mg/dL by the average glucose value in mg/dL, then multiplying times 100 to achieve a unitless percent value | Posted | Mean | Standard Error | Percentage of coefficient of variation | From beginning of use of the FUSION system to end of use of the FUSION system, which will be a period of time of up to 24 hours |
|
|
|
| Secondary | Percent of All Glucose Values Within Glucose Range > 250 mg/dL | Calculated by dividing the number of glucose values > 250 mg/dl by the total number of all glucose values and then multiplying times 100 | Posted | Mean | Standard Deviation | Percentage of all glucose values | From beginning of use of the FUSION system to end of use of the FUSION system, which will be a period of time of up to 24 hours |
|
|
|
| Other Pre-specified | Average Glucose Value | Calculate the average glucose value by adding up all glucose values and then dividing by the total number of glucose values that were added up | Posted | Mean | Standard Deviation | mg/dL | From beginning of use of the FUSION system to end of use of the FUSION system, which will be a period of time of up to 24 hours |
|
|
|
| 0 |
| 2 |
| 0 |
| 2 |
| 0 |
| 2 |
Not provided
Not provided
| D004700 | Endocrine System Diseases |